Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chelsea ANDA withdrawals

Executive Summary

FDA is proposing to withdraw nine ANDAs of the West Hempstead, New York-based generics manufacturer on the grounds that the applications contained untrue statements and that the products are not safe and effective. The ANDAs include verapamil 80 mg and 120 mg tablets (Calan), disopyramide 100 mg and 150 mg capsules (Norpace), perphenazine 4 mg/amitriptyline 50 mg tablets (Tiavil), oxazepam 10, 15 and 30 mg tablets (Serax), and perphenzing 8 mg tablets (Tilafon). Chelsea has until July 23 to request a hearing.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017647

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel